ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion

Ach Umsatz und EPS sind hier relativ zweitrangig. Da geht's eher um FDA Approvals, Pipeline etc.

Hab das Gefühl das es morgen runtergeht da die Schätzungen verfehlt wurden 🙈 Hoffentlich täusche ich mich 😅

https://www.stocktitan.net/news/CLPT/clear-point-neuro-reports-second-quarter-2021-g1p8jrp7djsn.html Record Case Volume Supported Clinically During the Quarter Second Quarter Highlights • Reported revenue of $3.4 million, a 38% year-over-year increase; • Clinical team supported a record 249 cases, a 98% year-over- year increase; • Increased biologics and drug delivery revenue to $1.4 million, a 19% year-over-year increase; • Added biologics and drug delivery relationships bringing current count of active partners to approximately 35 from approximately 30 in Q1 2021; and • Announced FDA clearance of the SmartFrame Array and performed first human cases. Business Outlook • The Company continues to estimate total case volume supported to be in the range of 900 – 1000 for 2021; and • The Company continues to estimate revenue to be between $16.0 and $17.5 million for 2021. ...

ClearPoint Neuro reports second quarter 2021 results - record case volume supported clinically during the quarter. #CLPT #earnings https://t.co/HAqlR2Owhz

ClearPoint Neuro, Inc. Announces Strategic and Commercial Partnership with European Surgical Equipment Leader adeor medical AG https://www.globenewswire.com/news-release/2021/08/09/2277039/25687/en/ClearPoint-Neuro-Inc-Announces-Strategic-and-Commercial-Partnership-with-European-Surgical-Equipment-Leader-adeor-medical-AG.html

ClearPoint Neuro: Path To Being The Neurological Navigation Platform Company https://seekingalpha.com/article/4446043-clearpoint-neuro-stock-path-to-being-the-neurological-navigation-platform Summary • ClearPoint Neuro is both a medical device and a biologics & drug delivery company. Both opportunities leverage a common navigation system with superior advantages over existing solutions. • New product developments in the pipeline allow them to penetrate into 90% of the operating room surgeries which they are not in today. • With a target to be in 100 centers conducting 100 cases each, 30 biologics & drug delivery partners, we believe the business to be worth at least $600M by 2025.

Danke 👍

We're proud to announce installation of our system at Hôpital Fondation Rothschild Paris advancing our strategy to set up more trial centers in the EU, UK & Middle East to support both our biologics & device partnerships. See more: https://t.co/ooEDMBOPT6 @FondARothschild #CLPT https://t.co/3ENpIhIWYa

Watch

Blackrock Neurotech, ClearPoint Neuro to Address Neurological Disorders With Novel Brain-Computer Interface Surgical Solution https://www.globenewswire.com/news-release/2021/07/21/2266822/25687/en/Blackrock-Neurotech-ClearPoint-Neuro-to-Address-Neurological-Disorders-With-Novel-Brain-Computer-Interface-Surgical-Solution.html

ClearPoint Neuro, Inc. Announces Installation of ClearPoint® 2.0 Software at Mazowiecki Szpital Bródnowski in Poland https://www.globenewswire.com/news-release/2021/06/16/2248533/0/en/ClearPoint-Neuro-Inc-Announces-Installation-of-ClearPoint-2-0-Software-at-Mazowiecki-Szpital-Br%C3%B3dnowski-in-Poland.html

Danke dir 👍

Nettes write up imo 😎 https://maxwellhouse99.substack.com/p/2-clearpoint-neuro-insane-in-the?r=cu51m&utm_campaign=post&utm_medium=web&utm_source=twitter

ClearPoint Neuro Set to Join Russell 3000® Index https://www.globenewswire.com/news-release/2021/06/14/2246614/0/en/ClearPoint-Neuro-Set-to-Join-Russell-3000-Index.html ...is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4.   ....

💎👍🏻

ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease https://www.globenewswire.com/news-release/2021/06/08/2243505/25687/en/ClearPoint-Neuro-Inc-Congratulates-BlueRock-Therapeutics-on-First-Patient-Dosed-with-DA01-in-Phase-1-Study-in-Patients-with-Advanced-Parkinson-s-Disease.html First Ever Stem Cell Clinical Trial Patient Treated Using Entire ClearPoint Platform